The Prostate
Prognostic Impact of Initial Prostate Specific Antigen Half-Life After Abiraterone Acetate in High-Volume Metastatic Hormone-Sensitive Prostate Cancer: Who May Need Triplet Therapy?
Kotaro Suzuki, Hideto Ueki, Naoto Wakita, Yasuyoshi Okamura, Yukari Bando, Takuto Hara, Tomoaki Terakawa, Yoji Hyodo, Koji Chiba, Jun Teishima, Hideaki Miyake
Published: 202610.1002/pros.70127
Abstract
BACKGROUND: As no randomized study has compared abiraterone acetate (ABI) doublet and triplet therapy, the optimal target for the add-on of docetaxel (DTX) to ABI doublet therapy remains unclear. The present study explored patients who may benefit fr…
Preview only. Read the full abstract at the source